Partagez | 


Voir le sujet précédent Voir le sujet suivant Aller en bas 
Rang: Administrateur

Nombre de messages : 15983
Date d'inscription : 23/02/2005

MessageSujet: Re: Salirasib   Mer 16 Mai 2012 - 19:53

On 21 June 2011, orphan designation (EU/3/11/871) was granted by the European Commission to TMC Pharma Services Ltd, United Kingdom, for salirasib for the treatment of pancreatic cancer.

Le 21 juin 2011 le médicament a reçu la désignation de médicament orphelin par la commission européenne pour le traitement du cancer du

What is the estimated number of patients affected by the condition?At the time of designation, pancreatic cancer affected approximately 1 in 10,000 people in the European Union (EU)*. This is equivalent to a total of around 51,000 people, and is below the ceiling for orphan designation, which is 5 people in 10,000. This is based on the information provided by the sponsor and the knowledge of the Committee for Orphan Medicinal Products (COMP).

Revenir en haut Aller en bas
Voir le profil de l'utilisateur
Rang: Administrateur

Nombre de messages : 15983
Date d'inscription : 23/02/2005

MessageSujet: Salirasib   Jeu 23 Juil 2009 - 12:11

Every year, 42,000 Americans are diagnosed with pancreatic cancer. Few live very long, and less than 5% are still alive five years after diagnosis.

Chaque année, 42,000 américains sont diagnostiqués avec le cancer du

There's new hope, though, from the lab of Prof. Yoel Kloog, dean of TAU's Faculty of Life Sciences. His drug compound Salirasib has shown positive results against pancreatic cancer and recently passed Phase I/II clinical trials. The drug, given in combination with gemcitabine, the standard drug used to combat pancreatic cancer, almost doubled the life expectancy of those who received it.

Il y a un nouvel espoir : la molécule Salirasib qui a démontré des résultats contre le cancer du :pancréas: Le médicament donné en combinaison avec le médicament habituel le gemcitabine double la durée de survie

"In our study, the mean survival of pancreatic cancer patients was 10.8 months — better by far than the 6.2 months with gemcitabine alone," says Prof. Kloog, who recently presented the results to a meeting of the American Society of Clinical Oncology. His basic research offers the promise of a weapon to attack a broader range of mankind's most prevalent diseases, including lung, prostate and breast cancers as well as diabetes.

La recherche du prof Kloog offre des promesses contre différente maladie inculant le cancer du du dela et le diabète.

Blocking the Ras protein

Salirasib works by inhibiting a protein called Ras, which is known to be abnormally activated in one-third of human cancers. In cancer of the pancreas, mutant forms of Ras are found in up to 90% of all tumors. Salirasib's basic component, FTS, works to block the formation of cancer-promoting Ras nanoclusters, thus blocking a cascade of biochemical signals known as the "Ras signaling pathway" that allow Ras to wreak havoc on the body.

Salirasib fonctionne en inhibant la protéine Ras qui est reconnu pour son activité anormal dans le tiers des cancers. Dans le cancer du pancréas des formes mutés de Ras sont trouvé dans 90% des cancers

Early in the 1990s, many drug developers chased after a mechanism to inhibit Ras by targeting enzymes that modify it, but they were unsuccessful. "The major developers gave up, claiming Ras is not targetable," says Prof. Kloog, "but our concept takes a different approach. Now that we've shown it works in human subjects, I am definitely excited — no doubt about it." Prof. Kloog developed the Ras antagonist more than 15 years ago.

Dans les années 90, plusieurs médicaments ont essayés de trouver le mécanisme pour inhiber Ras mais ils furent des échecs. Les plus gros joueurs ont abandonnés en disant que Ras n'étaient pas "ciblable" mais notre approche a adopté une tactique différente. "Maintenant que nous avons montré que cela marche dans des sujets humains, je suis très excité et je n'ai pas de doute à son sujet" dit le prof Kloog le développeur du médicament.

No toxic side effects

Pas d'effets toxiques

In the latest study, researchers tested for both toxicity and effectiveness. They gave 19 patients with advanced pancreatic cancer daily doses of salirasib along with a standard gemcitabine regimen. Salirasib was well tolerated by the patients, and they surpassed on average the number of months they would have lived on gentamiacine alone. There were no toxic side effects, such as heart or lung ailments. Tumor biopsies showed a significant reduction in Ras levels, suggesting that the drug is inhibiting the action of Ras in the tumor itself.

For this study, Salirasib was licensed by Concordia Pharmaceuticals, which collaborated with the Memorial Sloan Kettering Cancer Center, Johns Hopkins, the M.D. Anderson Cancer Center and other institutes in the United States.

If Phase II/III trials are successful, Prof. Kloog's drug will be the first successful Ras antagonist known to medical science. Salirabib could be medically available in as little as two years.

Si les phases II/III sont des réussites le Salirasib pourrait être disponible dans 2 ans.
Revenir en haut Aller en bas
Voir le profil de l'utilisateur
Voir le sujet précédent Voir le sujet suivant Revenir en haut 
Page 1 sur 1
 Sujets similaires
» Salirasib

Permission de ce forum:Vous ne pouvez pas répondre aux sujets dans ce forum
ESPOIRS :: Cancer :: recherche-
Sauter vers: